论文部分内容阅读
采用小剂量肝素治疗慢性重症肝炎患者２０例，并与综合治疗组做对照。结果肝素治疗组的病死率为３５％，显著低于对照组（６５％）；早、晚期慢重肝患者中，两组的病死率无差异，中期肝素治疗组的病死率（２７．２７％）低于对照组（７２．７２％）；经治疗后，凝血酶原时间（ＰＴ）继续延长和凝血酶原活动度（ＰＴＡ）继续降低者中，肝素治疗组仅１０％，对照组为２５％；因大出血死亡者肝素治疗组占５％，对照组占１０％，两组无明显差异。认为小剂量肝素治疗慢性重症肝炎是安全有效的，但宜早期应用。
Twenty patients with chronic severe hepatitis were treated with low-dose heparin and compared with the comprehensive treatment group. Results The mortality rate of heparin treatment group was 35%, which was significantly lower than that of control group (65%). There was no difference in mortality between early and late patients with chronic severe hepatitis, and the mortality rate of middle heparin treatment group (27.27% ) Was lower than that of the control group (72.72%). After treatment, prothrombin time (PT) continued to extend and prothrombin activity (PTA) continued to decline in the heparin treatment group was only 10%, the control group was 25 %; Heparin treatment group died of major bleeding accounted for 5%, control group accounted for 10%, no significant difference between the two groups. Small doses of heparin treatment of chronic severe hepatitis is safe and effective, but should be early application.